/MNKD
MNKD Stock - MannKind Corporation
Healthcare|BiotechnologyNASDAQ
$5.84-2.18%
$0.13 (-2.18%) • Dec 19
85
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.90
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.87
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+54.1%upside
Target: $9.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for MNKD
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$5.78 – $5.90
TARGET (TP)$9.00
STOP LOSS$5.37
RISK/REWARD1:6.7
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.82
52W High$7.04
52W Low$3.38
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $285.50M | $198.96M | $99.77M | $75.44M | $65.14M |
| Gross Profit | $208.90M | $136.19M | $42.27M | $36.59M | $40.50M |
| Gross Margin | 73.2% | 68.5% | 42.4% | 48.5% | 62.2% |
| Operating Income | $72.59M | $8.68M | $-64,110,000 | $-47,022,000 | $-47,913,000 |
| Net Income | $27.59M | $-11,938,000 | $-87,400,000 | $-80,926,000 | $-57,240,000 |
| Net Margin | 9.7% | -6.0% | -87.6% | -107.3% | -87.9% |
| EPS | $0.10 | $-0.04 | $-0.44 | $-0.37 | $-0.26 |
Company Overview
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
10
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
10 Bullish0 Neutral/Bearish
Price Targets
$9
Average Target
↑ 60.3% Upside
Now
$7
Low
$9
Average
$12
High
Based on 11 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 24th 2025 | Truist | Initiation | Buy | - |
| November 13th 2025 | Leerink Partners | Initiation | Outperform | $7 |
| October 20th 2025 | Wells Fargo | Initiation | Overweight | $10 |
| October 10th 2025 | Leerink Partners | Initiation | Outperform | $9 |
| July 16th 2025 | H.C. Wainwright | Resumed | Buy | $9 |
| April 10th 2025 | Mizuho | Initiation | Outperform | $12 |
| February 10th 2025 | Wedbush | Initiation | Outperform | $11 |
| December 20th 2024 | Wells Fargo | Initiation | Overweight | $9 |
| December 19th 2024 | RBC Capital Mkts | Upgrade | Outperform | $10← $7 |
| September 9th 2024 | Leerink Partners | Resumed | Outperform | $8← $7 |
| June 13th 2024 | Rodman & Renshaw | Initiation | Buy | $8 |
| October 10th 2023 | Wedbush | Initiation | Outperform | $10 |
Earnings History & Surprises
MNKDBeat Rate
47%
Last 17 quarters
Avg Surprise
+26.8%
EPS vs Estimate
Beats / Misses
8/7
2 met exactly
Latest EPS
$0.03
Q4 2025
EPS Surprise History
Q1 24
No data
Q2 24
+53.8%
$0.04vs$0.03
Q3 24
+249.9%
$0.05vs$-0.03
Q4 24
-33.3%
$0.04vs$0.06
Q1 25
0.0%
$0.03vs$0.03
Q2 25
+33.3%
$0.04vs$0.03
Q3 25
-94.6%
$0.00vs$0.04
Q4 25
+200.0%
$0.03vs$0.01
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q1 2026 | Feb 25, 2026 | $-0.01 | — | — | — |
Q4 2025 | Nov 5, 2025 | $0.01 | $0.03 | +200.0% | ✓ BEAT |
Q3 2025 | Aug 6, 2025 | $0.04 | $0.00 | -94.6% | ✗ MISS |
Q2 2025 | May 8, 2025 | $0.03 | $0.04 | +33.3% | ✓ BEAT |
Q1 2025 | Feb 26, 2025 | $0.03 | $0.03 | 0.0% | = MET |
Q4 2024 | Nov 7, 2024 | $0.06 | $0.04 | -33.3% | ✗ MISS |
Q3 2024 | Aug 7, 2024 | $-0.03 | $0.05 | +249.9% | ✓ BEAT |
Q2 2024 | May 8, 2024 | $0.03 | $0.04 | +53.8% | ✓ BEAT |
Q1 2024 | Feb 27, 2024 | — | $0.02 | — | — |
Q4 2023 | Nov 7, 2023 | $0.01 | $0.02 | +160.8% | ✓ BEAT |
Q3 2023 | Aug 7, 2023 | $-0.01 | $-0.02 | -47.4% | ✗ MISS |
Q2 2023 | May 9, 2023 | $-0.05 | $-0.04 | +20.0% | ✓ BEAT |
Q1 2023 | Feb 23, 2023 | $-0.06 | $-0.07 | -16.7% | ✗ MISS |
Q4 2022 | Nov 8, 2022 | $-0.10 | $-0.06 | +40.0% | ✓ BEAT |
Q3 2022 | Aug 9, 2022 | $-0.09 | $-0.11 | -22.2% | ✗ MISS |
Q2 2022 | May 5, 2022 | $-0.10 | $-0.10 | 0.0% | = MET |
Q1 2022 | Feb 24, 2022 | $-0.06 | $-0.11 | -83.3% | ✗ MISS |
Q4 2021 | Nov 9, 2021 | $-0.05 | $-0.04 | +20.0% | ✓ BEAT |
Q3 2021 | Aug 11, 2021 | $-0.04 | $-0.05 | -25.0% | ✗ MISS |
Latest News
MannKind Announces FDA Accepted For Review Its sNDA Of FUROSCIX ReadyFlow Autoinjector
📈 PositiveBenzinga•Dec 1, 2025, 01:08 PM
Truist Securities Initiates Coverage On MannKind with Buy Rating, Announces Price Target of $9
📈 PositiveBenzinga•Nov 24, 2025, 05:59 PM
RBC Capital Maintains Outperform on MannKind, Lowers Price Target to $7.5
➖ NeutralBenzinga•Nov 11, 2025, 03:26 PM
Wells Fargo Maintains Overweight on MannKind, Lowers Price Target to $8
➖ NeutralBenzinga•Nov 11, 2025, 02:33 PM
MannKind slides after halting late-stage trial of MNKD-101 for lung disease
📉 NegativeSeeking Alpha•Nov 10, 2025, 02:05 PM
MannKind Discontinues Its Phase 3 ICoN-1 Clinical Trial Evaluating MNKD-101, A Nebulized Clofazimine Inhalation Suspension, For Refractory Nontuberculous Mycobacterial Lung Disease
📉 NegativeBenzinga•Nov 10, 2025, 01:07 PM
Mannkind rises after Q3 revenue, profit beat
📈 PositiveSeeking Alpha•Nov 5, 2025, 02:56 PM
MannKind shares are trading higher after the company reported better-than-expected Q3 financial results.
📈 PositiveBenzinga•Nov 5, 2025, 02:31 PM
MannKind Q3 Adj. EPS $0.07 Beats $0.02 Estimate, Sales $82.130M Beat $80.255M Estimate
📈 PositiveBenzinga•Nov 5, 2025, 01:05 PM
FDA Accepts For Review MannKind's Supplemental Biologics License Application For Inhaled Insulin In Children 4-17 Years
📈 PositiveBenzinga•Oct 13, 2025, 12:10 PM
HC Wainwright & Co. Reiterates Buy on MannKind, Maintains $11 Price Target
📈 PositiveBenzinga•Oct 13, 2025, 11:12 AM
HC Wainwright & Co. Reiterates Buy on MannKind, Maintains $11 Price Target
📈 PositiveBenzinga•Sep 18, 2025, 10:17 AM
Oppenheimer Maintains Outperform on MannKind, Raises Price Target to $15
📈 PositiveBenzinga•Sep 5, 2025, 02:31 PM
Wells Fargo Maintains Overweight on MannKind, Raises Price Target to $10
📈 PositiveBenzinga•Sep 3, 2025, 12:58 PM
HC Wainwright & Co. Maintains Buy on MannKind, Raises Price Target to $11
📈 PositiveBenzinga•Sep 2, 2025, 04:16 PM
MannKind shares are trading higher after the company announced its deal with United Therapeutics will expand to develop a second inhaled therapy.
📈 PositiveBenzinga•Aug 27, 2025, 04:05 PM•Also:
MannKind rises as United Therapeutics exercises option for second inhalational drug
📈 PositiveSeeking Alpha•Aug 27, 2025, 02:42 PM•Also:
United Therapeutics Expands MannKind Deal To Develop Second Inhaled Therapy; MannKind To Receive $5M Upfront, Up To $35M In Milestones, And 10% Royalties
📈 PositiveBenzinga•Aug 27, 2025, 12:08 PM•Also:
RBC Capital Maintains Outperform on MannKind, Raises Price Target to $8
📈 PositiveBenzinga•Aug 26, 2025, 02:21 PM
HC Wainwright & Co. Reiterates Buy on MannKind, Maintains $9 Price Target
📈 PositiveBenzinga•Aug 25, 2025, 05:54 PM
Frequently Asked Questions about MNKD
What is MNKD's current stock price?
MannKind Corporation (MNKD) is currently trading at $5.84 per share. The stock has moved -2.18% today.
What is the analyst price target for MNKD?
The average analyst price target for MNKD is $9.00, based on 1 analyst.
What sector is MannKind Corporation in?
MannKind Corporation operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is MNKD's market cap?
MannKind Corporation has a market capitalization of $1.79 billion, making it a small-cap company.
Does MNKD pay dividends?
No, MannKind Corporation does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorABCL
AbCellera Biologics Inc.
$3.60
Mkt Cap: $1.1B
AUPH
Aurinia Pharmaceuticals Inc.
$16.18
Mkt Cap: $2.1B
BHVN
Biohaven Ltd.
$10.85
Mkt Cap: $1.1B
CLDX
Celldex Therapeutics, Inc.
$25.60
Mkt Cap: $1.7B
HRMY
Harmony Biosciences Holdings, Inc.
$37.81
Mkt Cap: $2.2B
IMCR
Immunocore Holdings plc
$36.01
Mkt Cap: $1.8B
JANX
Janux Therapeutics, Inc.
$13.79
Mkt Cap: $0.8B
NUVB
Nuvation Bio Inc.
$9.44
Mkt Cap: $3.2B
SION
Sionna Therapeutics, Inc.
$42.37
Mkt Cap: $1.9B
VERA
Vera Therapeutics, Inc.
$51.22
Mkt Cap: $3.3B
Explore stocks similar to MNKD for comparison